Healthcare / Medical DevicesSaudi
$86.60
+2.30 (+2.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-8.5M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$303M
P/E
7.3x
↓EV/EBITDA
7.7x
↓ROE
27.8%
↑Gross Margin
44.2%
↓Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+33.5%
FCF CAGR
—
FCF margin
-5.6%
FCF / Net income
-0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $418.8M · net income $41.7M · FCF $-23.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $418.8M | $418.8M | $313.2M | $250.1M | $176.1M |
| Net Income | $41.7M | $41.7M | $27.7M | $24.8M | $19.0M |
| EBITDA | $55.2M | $55.2M | $37.2M | $39.6M | $28.7M |
| EPS | — | — | 7.90 | 7.10 | 5.43 |
| Gross Margin | 44.2% | 44.2% | 44.3% | 44.8% | 47.5% |
| Operating Margin | 14.4% | 14.4% | 12.7% | 13.3% | 14.8% |
| Net Margin | 10.0% | 10.0% | 8.8% | 9.9% | 10.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 0.83 | 0.66 | 0.80 |
| Current Ratio | 1.55 | 1.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.5M | $-23.5M | $-8.5M | $-3.1M | $-10.4M |
| Returns | |||||
| ROE | 27.8% | 27.8% | 24.4% | 25.6% | 26.0% |
| Valuation | |||||
| P/E | 7.27 | 7.27 | 11.22 | 9.92 | — |
| EV/EBITDA | 7.70 | 7.70 | 10.73 | 7.82 | — |
| P/B | 2.02 | 2.02 | 2.74 | 2.53 | — |
| Growth & Yield | |||||
| Revenue Growth | 33.7% | 33.7% | 25.2% | 42.1% | — |
| EPS Growth | — | — | 11.3% | 30.7% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.7%
Start / end P/E
n/dx → n/dx
EPS bridge
7.90 → n/d
Residual
-5.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.